| Literature DB >> 26645709 |
H Versteeg1,2, J Denollet3, M Meine4, S S Pedersen3,5,6,7.
Abstract
BACKGROUND: Patient-reported factors have largely been neglected in search of predictors of response to cardiac resynchronisation therapy (CRT). The current study aimed to examine the independent value of pre-implantation patient-reported health status in predicting four-year survival and cardiac-related hospitalisation of CRT patients.Entities:
Keywords: Cardiac resynchronisation therapy; Health status; Heart failure; KCCQ; Prognosis
Year: 2016 PMID: 26645709 PMCID: PMC4692829 DOI: 10.1007/s12471-015-0775-5
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380
Baseline characteristics stratified by pre-implantation health status, and by cardiac-related hospitalisation or all-cause death during follow-up
| Pre-implantation characteristic | Total | Poor health status | Good health status |
| Event | Event-free |
|
|---|---|---|---|---|---|---|---|
| (n if ≥ 5 % missing values) | ( | ( | ( | ( | ( | ||
|
| |||||||
| Age, mean (SD) | 66 (10) | 65 (10) | 66 (11) | 0.69 | 66 (10) | 66 (10) | 0.83 |
| Male sex | 97 (70) | 28 (57) | 69 (77) | 0.02* | 48 (79) | 49 (63) | 0.04* |
| Having a partner | 113 (81) | 37 (76) | 76 (84) | 0.20 | 46 (75) | 67 (86) | 0.12 |
| Lower educationa | 18 (13) | 13 (27) | 5 (6) | <0.001*** | 12 (20) | 6 (8) | 0.04* |
| Currently employed | 30 (22) | 6 (13) | 24 (27) | 0.06 | 8 (13) | 22 (28) | 0.04* |
|
| |||||||
| Upgradeb | 36 (26) | 14 (29) | 22 (24) | 0.60 | 18 (30) | 18 (23) | 0.39 |
| Ischaemic aetiology | 68 (49) | 29 (59) | 42 (47) | 0.16 | 31 (51) | 37 (47) | 0.69 |
| NYHA class III/IV | 110 (79) | 47 (96) | 63 (70) | <0.001*** | 53 (87) | 57 (73) | 0.05* |
| LVEF, mean (SD) | 25 (9) | 26 (8) | 24 (9) | 0.26 | 25 (9) | 25 (8) | 0.56 |
| Atrial fibrillation ( | 20 (16) | 9 (20) | 11 (13) | 0.32 | 12 (24) | 8 (10) | 0.05* |
| QRS (ms), median (IQR), ( | 160 (140–180) | 160 (150–180) | 160 (140–180) | 0.52 | 160 (140–180) | 160 (145–180) | 0.76 |
| History of VT/VF | 26 (19) | 10 (20) | 16 (18) | 0.70 | 14 (23) | 12 (15) | 0.26 |
| Left bundle branch block ( | 60 (54) | 21 (60) | 39 (51) | 0.40 | 24 (55) | 36 (54) | 0.93 |
| Diabetes mellitus | 30 (22) | 11 (22) | 19 (21) | 0.86 | 10 (16) | 20 (26) | 0.19 |
| COPD | 22 (16) | 13 (27) | 9 (10) | 0.01* | 12 (20) | 10 (13) | 0.27 |
| Renal failurec | 50 (36) | 16 (33) | 34 (38) | 0.55 | 27 (44) | 23 (30) | 0.07 |
| Body mass index, median (IQR) | 26 (24–29) | 27 (24–31) | 26 (23–29) | 0.08 | 26 (24–29) | 25 (24–31) | 0.72 |
| Smoking | 21 (15) | 11 (22) | 10 (11) | 0.08 | 8 (13) | 13 (17) | 0.56 |
|
| |||||||
| Amiodarone | 17 (12) | 6 (12) | 11 (12) | 1.0 | 8 (13) | 9 (12) | 0.78 |
| ACE inhibitors/ARBs | 126 (91) | 43 (88) | 83 (92) | 0.39 | 58 (95) | 68 (87) | 0.11 |
| Beta blockers | 108 (78) | 35 (71) | 73 (81) | 0.19 | 48 (78) | 60 (77) | 0.80 |
| Digoxin | 23 (17) | 10 (20) | 13 (14) | 0.37 | 11 (18) | 12 (15) | 0.68 |
| Diuretics | 118 (85) | 42 (86) | 76 (84) | 0.84 | 52 (85) | 66 (85) | 0.92 |
| Statins | 84 (60) | 30 (61) | 64 (60) | 0.89 | 38 (62) | 46 (59) | 0.69 |
|
| |||||||
| Anxiety (STAI-S ≥ 40) | 59 (43) | 34 (71) | 25 (28) | < 0.001*** | 24 (40) | 35 (45) | 0.52 |
| Depression (PHQ-9 ≥ 10) | 32 (23) | 25 (51) | 8 (9) | < 0.001*** | 17 (28) | 16 (21) | 0.31 |
| Type D personality | 32 (23) | 20 (41) | 12 (14) | < 0.001*** | 11 (18) | 21 (27) | 0.20 |
| Psychotropic medication | 33 (24) | 18 (37) | 15 (17) | 0.008** | 17 (28) | 16 (21) | 0.31 |
Data are presented as n(%), unless otherwise stated.
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, COPD chronic obstructive pulmonary disease, IQR interquartile range, LVEF left ventricular ejection fraction; ms milliseconds, NYHA New York Heart Association, PHQ-9 9-item Patient Health Questionnaire, SD standard deviation, STAI-S Stait-Trait Anxiety Inventory–State form; VT/VF ventricular tachycardia/fibrillation.
aPrimary school or lower.
bUpgrade from another implantable device, either (biventricular) pacemaker or implantable cardioverter defibrillator without cardiac resynchronisation therapy.
cRenal failure = creatinine > 120 µmol/L.
*p ≤ 0.05; ** p ≤ 0.01; ***p ≤ 0.001.
Fig. 1Cumulative event-free survival curves by pre-implantation KCCQ score
Adjusted Cox and negative binomial regression analysis
| First-time cardiac-related hospital admission or all-cause death | Total number of days in | |||||
|---|---|---|---|---|---|---|
| HR | 95 % CI |
| IRR | 95 % CI |
| |
| Poor health status | 2.46 | 1.30–4.65 | 0.005** | 3.20 | 1.88–5.44 | < 0.001*** |
| EAARN score ≥ 3 | 1.29 | 0.71–2.32 | 0.40 | 0.71 | 0.41–1.24 | 0.23 |
| Male sex | 2.07 | 1.02–4.19 | 0.04* | 1.53 | 0.84–2.82 | 0.17 |
| Diabetes and/or COPD | 1.04 | 0.58–1.89 | 0.89 | 0.65 | 0.38–1.12 | 0.12 |
| Unhealthy lifestylea | 0.82 | 0.45–1.50 | 0.52 | 0.35 | 0.19–0.64 | 0.001** |
| Psychological distressb | 1.12 | 0.61–2.08 | 0.71 | 0.84 | 0.53–1.34 | 0.47 |
| Ischaemic aetiology | 1.09 | 0.63–1.91 | 0.75 | |||
| QRS duration > 150 ms | 0.51 | 0.30–0.87 | 0.01** | |||
| Having a partner | 0.29 | 0.15–0.56 | < 0.001*** | |||
| Being employed | 0.24 | 0.12–0.48 | < 0.001*** | |||
EAARN score left ventricular ejection fraction < 22 %, age ≥ 70 years, atrial fibrillation, renal dysfunction (creatinine > 120 µmol/l), and New York Heart Association class III or IV.
CI confidence interval, COPD chronic obstructive pulmonary disease, HR hazard ratio, IRR incidence rate ratio, ms milliseconds.
aUnhealthy lifestyle = primary school or lower, body mass index > 30, and/or smoking.
bPsychological distress = clinically relevant anxiety, depression and/or Type D personality according to questionnaires, and/or being prescribed psychotropic medication.
*p ≤ 0.05; ** p ≤ 0.01; ***p ≤ 0.001.